Special Committee On Drug Prices – Industry Refutes Long-Term Product And Generic Drug Prices
This article was originally published in PharmAsia News
The Central Social Insurance Medical Council (Chuikyo) and Special Committee on Drug Prices, who are holding discussions regarding the next prescription drug pricing system reforms, heard expert opinions July 18 regarding drug price cuts and the promotion of the use of generic drugs.
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.